Clinical Microbiology Global Market Report 2024

The global clinical microbiology market has grown strongly in recent years. It will grow from $6.46 billion in 2023 to $6.9 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historical period can be attributed to various factors, including the rise of antimicrobial resistance, infectious disease outbreaks, the effects of globalization and increased travel, an aging population, and an overall increase in healthcare expenditure. These factors collectively contributed to the expansion witnessed during that timeframe.

The global clinical microbiology market is expected to see strong growth in the next few years. It will grow to $9.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period can be attributed to factors such as the demand for rapid results in clinical microbiology, a focus on personalized treatments, increasing demand for surveillance of infectious diseases, emphasis on healthcare-associated infections, and the integration of point-of-care testing. Major trends expected in the forecast period encompass the integration of omics technologies, collaborative innovation in the field, increased awareness of healthcare-associated infections, influence from regulatory measures, and continuous technological advancements. These trends collectively contribute to the projected growth in the upcoming period.

The surge in infectious diseases is anticipated to drive growth in the clinical microbiology market. Infectious diseases, caused by harmful microorganisms like bacteria, fungi, and parasites, pose significant health risks. Clinical microbiology plays a crucial role in isolating and characterizing these infectious organisms, enabling effective control and treatment of such diseases in patients. In 2021, Australia witnessed a noteworthy increase in notifiable infectious illness cases, reaching 7.02 million, as reported by the Australian Institute of Health and Wellbeing. This substantial rise underscores the heightened prevalence of infectious diseases. Consequently, the clinical microbiology market is expanding in response to the increased occurrence of infectious disorders.

The clinical microbiology market is set for growth propelled by the augmented public and private investments in clinical diagnostics. Increased funding from both sectors acts as a catalyst for advancements in diagnostic tools, laboratory capabilities, and public health responses to infectious diseases. The UK government's commitment to enhanced investment in medical device approval, as of February 2023, is indicative of this trend. Private equity investments of $111.8 billion in the healthTech industry in 2023, as reported by MedTech news, further contribute to the overall funding surge in clinical diagnostics, substantiating the growth of the clinical microbiology market.

Technological advancement emerges as a key trend driving the clinical microbiology market. Major players in the market are directing their efforts toward research and development to introduce innovative technologies such as proteomic fingerprinting for medical diagnosis. In July 2021, Bruker unveiled the MALDI Biotyper Sirius system, an advanced diagnostic product integrating proteomic fingerprinting. This system facilitates rapid, universal, and cost-effective microbial identification along with antibiotic resistance testing and comprehensive mycobacteria analysis post-culture, showcasing the industry's commitment to technological innovation.

Product innovations take center stage in the clinical microbiology market, with major companies focusing on developing new solutions to enhance patient care. Middleware systems like MAESTRIA are designed to revolutionize workflow management within clinical microbiology laboratories. Launched by bioMérieux in January 2023, MAESTRIA offers features such as workflow management, biological expertise, and data management, streamlining laboratory processes and optimizing surveillance reporting. The middleware is compatible with existing instruments and workflows, providing an integrated solution for microbiology laboratory processes.

Strategic acquisitions play a vital role in shaping the clinical microbiology market landscape. In April 2022, DCN Dx, a US-based company specializing in rapid point-of-care tests, acquired Biomed Diagnostics Inc. This acquisition aims to bolster DCN Diagnostics' product portfolio and market presence in microbial testing within the clinical microbiology domain. Biomed Diagnostics, a US-based manufacturer known for high-quality microbiology devices, adds valuable capabilities to DCN Dx, positioning them for growth in the clinical microbiology market.

Major companies operating in the clinical microbiology market report are bioMérieux SA, Danaher Corporation, BD, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Corporation, QIAGEN NV, 3M, Bio-Rad Laboratories Inc., Bruker Corporation, Hologic Inc., Agilent Technologies Inc., Merck Group, Shimadzu Corporation, Neogen Corporation, Vacutest Kima SRL, Arrow Diagnostics SRL, OpGen, Becton Dickinson and Company, Johnson & Johnson, Sanofi SA, Illumina Inc., Medtronic, Cepheid Inc., Quidel Corporation, Luminex Corporation, DiaSorin S.p.A., GenMark Diagnostics Inc., T2 Biosystems Inc., and Nanosphere Health Sciences Inc.

North America was the largest region in the clinical microbiology market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical microbiology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical microbiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main products associated with clinical microbiology include laboratory instruments, microbiology analyzers, and reagents. Laboratory instruments are employed for various laboratory operations such as diagnostics, experiments, and analysis. These instruments, which include vessels and tools, are used in laboratory settings without altering the physical and chemical properties of the products involved in operations. Clinical microbiology plays a crucial role in detecting indications related to respiratory diseases, sexually transmitted diseases, urinary tract infections, periodontal diseases, and other health conditions. The products in this field find application in hospitals, diagnostic laboratories, and other end-users involved in healthcare and medical research.

This report provides clinical microbiology market statistics, including clinical microbiology industry global market size, regional shares, competitors with a clinical microbiology market share, detailed clinical microbiology market segments, market trends and opportunities, and any further data you may need to thrive in the clinical microbiology industry. This clinical microbiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical microbiology market consists of sales of incubators, gram strainers, bacterial colony counters, autoclave sterilizers, microbial air samplers, and anaerobic culture systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.